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Abstract. A general and practical metal-free protocol for the synthesis of 1,2-dihydropyridines with a 
wide structural/functional diversity at the ring and featuring mono, double or spiro substitution at the sp
3
-
position is described. The protocol entails a microwave-assisted domino reaction of a propargyl vinyl 
ether (secondary or tertiary) and a primary amine (aliphatic or aromatic) in toluene or methanol.  
Keywords: 1,2-dihydropyridine, spiro compounds, domino reactions, propargyl vinyl ethers, 1-
azatrienes, microwave-assisted, propargyl Claisen rearrangement, 6-aza-electrocyclization. 
 
 
Dihydropyridines (DHPs) represent a group of organic scaffolds based on the pyridine 
ring.
1
 Among the five possible isomeric structures containing this motive, the 1,2- and the 1,4-
dihydro constitute the most populated group. Whereas the 1,4-DHPs have received a great 
attention due to their wide variety of biological and pharmacological actions,
2
 the biological 
annotation of 1,2-DHPs remains relatively unexplored,
3
 which converts them into a valuable 
candidate structure for the design of heterocyclic focused libraries. On the other hand, 1,2-DHPs 
have found important synthetic applications as cyclic aza-dienes in the Diels-Alder mediated 
preparation of isoquinuclidines,
4 
an important structural motive present in many 
pharmacologically relevant natural products
5
 as the alkaloids ibogaine (2)
6
 and catharanthine 
(3),
7




The synthesis of the 1,2–DHPs has been recently reviewed.9 Currently, these 
heterocyclic scaffolds are synthesized from activated pyridines (reduction, condensation)
10
 or  
 
 
Scheme 1. Isoquinuclidinic alkaloids. 
from the corresponding 1- azatrienes by a 6-aza-electrocyclization process.11,12 Although less 
general, azadienes have been also used as convenient precursors.
13,14
 Moreover, the first 
approach suffers from a reliance on the pyridine inputs which translates to a limited degree of 
substitution at the DHP’s ring. The second approach allows for wider degrees of substitution at 
the ring and it is better suited for diversity-oriented library construction. However, the key to 
this approach resides on the efficient access to highly functionalized 1-azatriene platforms. 
Currently, these platforms are formed in situ by coupling of vinylogous amides and α,β-







 have developed a direct protocol toward 1,2-DHPs 8 from propargyl 
vinyl ethers (PVEs) 4, using the propargyl Claisen rearrangement
15
 to directly deliver the 2,4-
dienals 6. In the presence of a primary amine, these units condense to generate the 
corresponding 1- azatrienes 7 which, by a 6-aza-electrocyclization process, construct the 
corresponding 1,2-DHPs 8.  
In spite of these advances, the domino synthesis of 1,2-DHPs from propargyl vinyl 
ethers still maintains a number of experimental limitations to become a robust, general and 
practical methodology with direct application in diversity-oriented synthetic programs. The 
main limitation is related to the grade of substitution at the sp
3
-position (for clarity, we will refer 
to this position as the C-2 position regardless of the other substituents on the ring). The current  
 
 
Scheme 2. 1-Azatriene-approach to 1,2-dihydropyridines. 
methodology synthesizes 1,2-DHPs bearing only one substituent at this position. The 
introduction of a second substituent should allow the access to quaternary or spiro motives 
which not only should increase the degree of structural diversity but should also provide new 
chemotypes with unpredictable biological (pharmaceutical) properties. The establishment of a 
simple and efficient access to spiro 1,2-DHPs should pave the way to the construction of 
chemical libraries with high value in medicinal chemistry.
16
 The number of reported 
methodologies to access quaternary/spiro 1,2-DHPs is really scarce.
17
 Besides this general 
limitation, our own approach to these scaffolds
12b
 showed a particular structural restraint 
regarding internal alkynes (R
1 ≠ H, Scheme 2a). In these cases, the reaction did not tolerate an 
alkyl substituent at the propargylic position (R
2 ≠ Alk). This restriction has also been reported 
by Xu and col.
12c
 in their Au/Ag-catalyzed domino protocol. Interestingly, Kirsch and col.
12a
 
have described an Au-catalyzed one-pot protocol which overrides this substituents restraint but 
poses a new structural limitation on the use of terminal alkynes. In this note we describe our 
advances in the development of a metal-free protocol able to deliver these important 
heterocyclic scaffolds with a wide structural/functional diversity at the ring and featuring mono, 
double or spiro substitution at the sp
3
-position. The protocol entails a microwave-assisted 
domino reaction involving a propargyl vinyl ether (secondary or tertiary)
18
 and a primary amine. 
The manifold constructs 1,2-DHPs featuring a wide array of topologies spanning from simple 
monocyclic scaffolds to spiro derivatives. The protocol tolerates a topologically diverse 
substitution pattern at the triene terminus of the 1-azatriene intermediate 7 which is directly 
delivered to the C-2 position of the final 1,2-DHP (Table 1). 











and p-methoxyaniline (1.1 eq) under the microwave conditions established in our 
previous protocol [toluene,  (120 ºC, 150 W, 1h, closed vessel)].12b Under these conditions, 
the quaternary 1,2-DHP 8a was cleanly obtained in an excellent 93% yield. Other tertiary PVEs 
also delivered the corresponding quaternary 1,2-DHPs in excellent yields. Thus, for example, 
the PVEs 4b and 4c were cleanly transformed into the corresponding products 8b and 8c in 92% 
and 94% yield respectively. The manifold was able to transform the monocyclic tertiary PVEs 
4d and 4e into the spiro derivatives 8d and 8e with high efficiency (94% and 93% respectively). 
In our previous work,
12b
 we had performed the reaction of the secondary PVE 4f with (S)-1-
phenylethanamine obtaining the chiral 1,2-DHP 8f in excellent yield (83%) but modest 
diastereoselectivity (75:25). However, when the tertiary PVE 4g was submitted to the same set 
of reaction conditions, the chiral quaternary 1,2-DHP 8g was obtained with the same high  
Table 1. -Assisted domino synthesis of 1,2-dihydropyridines 8 from propargyl vinyl ethers 4.a 
 a




 3h, 150 ºC. PMP = p-Methoxyphenyl 
 
efficiency (83%) but with practically null diastereoselectivity (60:40). This decreasing in 
diastereoselectivity was in certain manner predictable according to the marked steric difference 
between a methyl group and hydrogen.
20
 Nevertheless, the two isomers could be separated by 
simple flash chromatography. When we attempted to perform the reaction using tertiary PVEs 
armed with internal alkynes (R
1 ≠ H), the yields considerably dropped down. This was the case 
of the spiro 1,2-DHP 8h which was obtained with a modest 43% yield. Fortunately, the use of 
methanol as the reaction solvent
21
 reverted the reaction’s efficiency back to the previous high 
levels, rendering the spiro derivative in 83% yield. Interestingly, the quaternary 1,2-DHP 8a  
could be also obtained under these new conditions (, methanol) but with a significant 
reduction in the yield (58%). These new conditions proved to be highly tolerant with the 
structure of the PVE (secondary or tertiary, internal alkyne) and the electronic nature of the 
primary amine (aliphatic or aromatic). It is remarkable the power of this reaction to generate 
diversity on the nitrogen atom regardless of the structure of the PVE: quite different primary 
amines (aliphatic, aromatic) are able to react with tertiary PVEs armed with electronically 
different alkyne moieties to afford the corresponding heterocyclic core with similar overall 
yields. This is the case of the spiro derivatives 8h (p-anisidine, 83%) and 8i (benzylamine, 
82%), or 8j (aniline, 76%), 8k (methylamine, 79%) and 8l (p-anisidine, 77%). The reaction 
showed high tolerance with the electronic nature of the internal alkyne moiety of the PVE. It is 
remarkable the generation of the spiro 1,2-DHP 8m. In spite of the steric congestion that a tert-
butyl group should introduce into the 1-azatriene intermediate 7m (Scheme 2b), this is formed 
and cyclized to generate 8m, although in a 15% yield. The reduction of the steric demand from 
a tert-butyl to a methyl substituent was mirrored in a net increase of the reaction efficiency 
(compare 8m with 8j-l). The reaction manifold also accepted acyclic tertiary PVEs to generate 
the corresponding quaternary derivatives (e.g., 8n, 81%). Cyclic tertiary PVEs 4o and 4p 
afforded the functionalized spiro 1,2-DHPs 8o and 8p in very good yields, although they need 
more time to be fully transformed into the final products. The extra functionalization 
incorporated at the spiro cycle (protected amine, masked ketone) constitutes a convenient 
chemical handle for further chemical access to this ring or for the generation of molecular 
complexity. Finally, the reaction was also able to override the structural limitation found in our 
previous model: the use of secondary PVEs armed with internal alkynes and alkyl substituents 
at the propargylic position. The 1,2-DHPs 8q-s are nice examples of this structural 
breakthrough. In these cases, the reaction needs more energy and more time (3h under 150 ºC 
and irradiation) to be accomplished. 
It is interesting to note that 1,2-DHPs 8j-l exist in equilibrium as mixtures of the “methyl” and 
“methylene” tautomers (endocyclic or exocyclic double bond respectively) (see supporting 
information for details). 
 
 
Scheme 3. Tautomeric equilibrium in 1,2-dihydropyridines. 
In summary, we have enhanced the practicality and generality of our previous metal-free 
synthetic protocol for the access to 1,2-DHPs from propargyl vinyl ethers and primary amines. 
This improved version delivers these important heterocyclic scaffolds with a wider diversity at 
the ring and mono, double or spiro substitution at the sp
3
-position. The protocol accepts 
secondary and tertiary
 
propargyl vinyl ethers bearing internal or terminal alkyne moieties and 




H NMR and 
13
C NMR spectra of CDCl3 solutions were 
recorded either at 400 and 100 MHz or at 500 and 125 MHz, respectively. Microwave 
reactions were conducted in sealed glass vessels (capacity 10 mL) using CEM Discover 
microwave reactor equipped with a surface sensor for temperature measuring of the 
reaction mixture. FT-IR spectra were measured in chloroform solutions using a FT-IR 
spectrophotometer. Mass spectra (low resolution) (EI/CI) and HRMS (EI/TOF) were 
obtained with a gas chromatograph/mass spectrometer. Analytical thin-layer 
chromatography plates used UV-active silica on aluminum. Flash column 
chromatography was carried out with silica gel of particle size less than 0.020 mm, 
using appropriate mixtures of ethyl acetate and hexanes as eluents. All reactions were 
performed in oven-dried glassware. All materials were obtained from commercial 
suppliers and used as received unless otherwise noted. When necessary, the propargyl 
alcohols were prepared by addition of the lithium acetylides onto the appropriate 











 have been previously prepared. 
General procedure for the synthesis of propargyl alcohols: A terminal alkyne (13 
mmol) was dissolved in 25 mL of dry THF in a round-bottom flask. After the mixture 
was cooled to -40ºC, a 1.6M solution of BuLi in hexanes (13 mmol) was added 
dropwise. The temperature was maintained for 1 hr with stirring of the solution. The 
ketone was then added slowly (if solid, dissolved in THF) and the stirring was 
continued overnight allowing the reaction mixture to warm up to room temperature 
slowly without additional cooling. After completion, the reaction was quenched with 
saturated NH4Cl solution and extracted with CH2Cl2. This was followed by isolation of 
the corresponding product by flash column chromatography (silica gel, appropriate 
mixtures of n-hexane/EtOAc). 
Representative procedure for the synthesis of propargyl vinyl ethers 4 from 
secondary or tertiary alcohols: methyl propiolate (2.6 mmol) was added dropwise 
(time of addition 10 minutes) to a solution of 1-(phenylethynyl)cyclopentanol (2.0 
mmol) and DABCO (0.20 mmol) in dry CH2Cl2 (5 mL). The reaction mixture was 
stirred for 5 min (TLC control). The solvent was removed under reduced pressure, and 
the residue was purified by flash column chromatography (silica gel; n-hexane/EtOAc, 
90:10) to give 4h (512 mg, 90 %). Less reactive alcohols were synthesized in n-hexanes 
to control the competitive dimerization of methyl propiolate.
19
  
(E)-methyl 3-(1,1-diphenylprop-2-ynyloxy)acrylate (4c): This product rearranges 
partially (around 15%) during isolation by column chromatography. The rearranged 
product has a similar Rf so the mixture can be used for the synthesis of the 
corresponding dihydropyridine. 
1
H NMR (CDCl3, 400 MHz): 2.79 (s, 1H), 3.64 (s, 
3H), 5.57 (d, 
3
J(H,H) = 12.1, 1H), 7.28-7.36 (m, 6H), 7.50-7.52 (m, 4H), 7.74 (d, 
3
J(H,H) = 
12.1, 1H).  
(E)-Methyl 3-(1-ethynylcyclopentyloxy)acrylate (4d): (361 mg, 93%) colorless oil. 
1
H NMR (CDCl3, 400 MHz): = 1.71-1.78 (m, 4H), 1.95-2.03 (m, 2H), 2.09-2.15 (m, 
2H), 2.64 (s, 1H), 3.67 (s, 3H), 5.37 (d, 
3
J(H,H)= 12.1 Hz, 1H), 7.76 (d, 
3
J(H,H)= 12.1 Hz, 
1H). 
13
C NMR (CDCl3, 100 MHz): = 23.3 (2C), 40.4 (2C), 51.0, 75.4, 83.0, 84.2, 
100.0, 158.6, 168.1. IR (CHCl3, cm
-1
) 3305.5, 2954.0, 2118.6, 1702.3, 1641.0, 1438.3, 
1333.5, 1294.9, 1169.8. MS (70 eV): m/z (%): 194 (2.0) [M
+
], 135 (11), 103 (14), 93 
(81), 92 (37), 91 (100), 77 (89), 65 (28). HRMS calculated for C11H14O3 194.0943, 
found 194.0945. 
(E)-methyl 3-(1-(phenylethynyl)cyclopentyloxy)acrylate (4h): (512 mg, 90%) 
colorless oil. 
1
H NMR (CDCl3, 400 MHz): 1.80-1.84 (m, 4H), 2.05-2.12 (m, 2H), 
2.19-2.23 (m, 2H), 3.69 (s, 3H), 5.41 (d, 
3
J(H,H) = 12.1, 1H), 7.28-7.32 (m, 3H), 7.42-
7.45 (m, 2H), 7.89 (d, 
3
J(H,H) = 12.1, 1H). 
13
C NMR (CDCl3, 100 MHz): = 23.5 (2C), 
40.6 (2C), 51.0, 85.1, 87.2, 88.1, 99.8, 122.0, 128.3 (2C), 128.7, 131.8 (2C), 159.0, 
158.2. IR (CHCl3, cm
-1
) 3015.49, 2953.95, 2878.33, 2230.20, 1701.20, 1638.73, 
1558.93, 1540.42, 1490.37, 1438.07, 1334.77, 1294.38, 1222.25, 1209.89, 1166.91, 
1135.38, 1050.74. MS (70 eV): m/z (%): 270 (1.7) [M
+
], 211 (11), 169 (100), 154 (29), 
141 (75), 128 (37), 115 (77), 91 (80), 77 (13), 67 (11). HRMS calculated for C17H18O3 
270.1256, found 270.1259. 
(E)-Methyl 3-(1-(prop-1-ynyl)cyclohexyloxy)acrylate (4j): (435 mg, 98%) colorless 
oil. Repeated on 20 mmol scale obtaining the same yield. 
1
H NMR (CDCl3, 400 MHz): 
= 1.23-1.33 (m, 1H), 1.44-1.57 (m, 3H), 1.59-1.70 (m, 4H), 1.83-1.87 (m, 2H), 1.87 
(s, 3H), 3.67 (s, 3H), 5.35 (d, 
3
J(H,H)= 12.1 Hz, 1H), 7.92 (d, 
3
J(H,H)= 12.1 Hz, 1H). 
13
C 
NMR (CDCl3, 100 MHz): = 3.6, 22.5 (2C), 24.8, 37.9 (2C), 50.9, 78.5, 79.0, 84.6, 
98.7, 158.8, 168.5. IR (CHCl3, cm
-1
) 2942.6, 2860.5, 2241.6, 1701.5, 1636.9, 1438.3, 
1334.4, 1305.5, 1231.5, 1133.1. MS (70 eV): m/z (%): 222 (2.6) [M
+
], 179 (3.8), 163 
(5.6), 121 (100), 105 (12), 93 (29), 91 (14), 79 (14). HRMS calculated for C13H18O3 
222.1256, found 222.1250. 
(E)-methyl 3-(1-(3,3-dimethylbut-1-ynyl)cyclohexyloxy)acrylate (4m): (486 mg, 
92%) colorless oil. 
1
H NMR (CDCl3, 400 MHz): = 1.21-1.34 (m, 1H), 1.26 (s, 9H), 
1.51-1.60 (m, 3H), 1.65-1.70 (m, 4H), 1.88-1.92 (m, 2H), 3.71 (s, 3H), 5.38 (d, 
3
J(H,H)= 
12.1 Hz, 1H), 8.00 (d, 
3
J(H,H)= 12.1 Hz, 1H). 
13
C NMR (CDCl3, 100 MHz): = 22.8 
(2C), 24.9, 27.5, 30.9 (3C), 38.1 (2C), 50.8, 77.7, 79.3, 98.3, 98.5, 158.9, 168.5. IR 
(CHCl3, cm
-1
) 2971.8, 2942.2, 2863.6, 2231.0, 1702.1, 1636.3, 1438.4, 1334.4, 1191.6. 
MS (70 eV): m/z (%): 264 (0.9) [M
+
], 163 (100), 121 (30), 107 (46), 95 (37), 93 (29), 91 
(24), 81 (25). HRMS calculated for C16H24O3 264.1725, found 264.1729. 
(E)-methyl 3-(8-(phenylethynyl)-1,4-dioxaspiro[4.5]decan-8-yloxy)acrylate (4o). 
(671 mg, 98%) colorless oil: 
1
H NMR (CDCl3, 400 MHz): m 2.13 
(pseudo t, 
3
J(H,H) = 6.3, 4H), 3.67 (s, 3H), 3.93 (s, 4H), 5.44 (d, 
3
J(H,H) = 12.1, 1H), 7.27-
7.35 (m, 3H), 7.42-7.44 (m, 2H), 7.97 (d, 
3
J(H,H) = 12.1, 1H) . 
13
C NMR (CDCl3, 100 
MHz): = 30.8 (2C), 35.2 (2C), 50.9, 64.4 (2C), 77.4, 87.2, 88.2, 99.8, 107.3, 121.7, 
128.3 (2C), 128.9, 131.8 (2C), 158.1, 168.1. IR (CHCl3, cm
-1
) 2955.69, 2887.50, 
2226.76, 1703.49, 1639.32, 1490.25, 1438.38, 1374.26, 1335.76, 1293.65. MS (70 eV): 
m/z (%): 342 (1.1) [M
+
], 241 (100), 197 (23), 179 (34), 141 (11), 127 (12), 115 (12), 99 
(21), 86 (13). HRMS calculated for C20H22O5 342.1467, found 342.1469. 
(E)-methyl 3-(1-benzyl-4-(phenylethynyl)piperidin-4-yloxy)acrylate (4p): (735 mg, 
98%) colorless oil. 
1
H NMR (CDCl3, 400 MHz): mm, 
2H), 2.63-2.67 (m, 2H), 3.53 (s, 2H), 3.69 (s, 3H), 5.47 (d, 
3
J(H,H) = 12.1, 1H), 7.25-7.27 
(m, 1H), 7.25-7.27 (m, 1H), 7.31-7.33 (m, 7H), 7.44-7.46 (m, 2H), 7.99 (d, 
3
J(H,H) = 
12.1, 1H) . 
13
C NMR (CDCl3, 100 MHz): = 37.3 (2C), 49.5 (2C), 50.9, 62.6, 77.1, 
87.3, 89.0, 99.8, 121.7, 127.1, 128.2 (2C), 128.3 (2C), 128.91, 128.93 (2C), 131.8 (2C), 
138.4, 158.1, 168.1. IR (CHCl3, cm
-1
) 3028.72, 2952.64, 2814.99, 2226.76, 1705.38, 
1639.61, 1490.58, 1438.29. MS (70 eV): m/z (%): 375 (4.9) [M
+
], 347 (10), 274 (75), 
182 (8.2), 146 (6.7), 155 (6.4), 91 (100). HRMS calculated for C24H25NO3 375.1834, 
found 375.1848. 
(E)-Methyl 3-((1-phenylhept-6-en-1-yn-3-yl)oxy)acrylate (4q): (569 mg, 97%) 
colorless oil. 
1
H NMR (CDCl3, 400 MHz): 1.87-2.02 (m, 2H), 2.19-2.25 (m, 2H), 
3.62 (s, 3H),  4.71 (t, 
3
J(H,H) = 6.6, 1H),  4.95-5.03 (m, 2H), 5.35 (d, 
3
J(H,H) = 12.6, 1H) 
5.70-5.80 (m, 1H),  7.21-7.27 (m, 3H), 7.35-7.37 (m, 2H), 7.60 (d, 
3
J(H,H) = 12.6, 1H). 
13
C NMR (CDCl3, 100 MHz): = 29.1, 34.5, 51.1, 71.4, 85.1, 88.1, 98.6, 115.9, 121.8, 
128.3, 128.9, 131.8, 136.7, 160.6, 168.1. IR (CHCl3, cm
-1
) 3082.8, 3063.5, 3026.7, 
3013.5, 2953.7, 2850.1, 2229.4, 2205.1, 1706.1, 1642.8, 1624.2, 1491.2, 1438.6, 
1416.9, 1333.8, 1292.9, 1222.7, 1209.5, 1191.8, 1141.8, 1070.6, 1050.0. HRMS (ESI) 
m/z calculated for C17H18O3Na [M + Na]
+
 293.1154, found 293.1158. 
 (E)-Methyl 3-(1-cyclohexyl-3-phenylprop-2-ynyloxy)acrylate (4r): (584 mg, 98%) 
yellowish oil. 
1
H NMR (CDCl3, 400 MHz): 1.10-1.34 (m, 5H), 1.68-1.70 (m, 1H), 
1.73-1.84 (m, 3H), 1.88-1.93 (m, 2H), 3.69 (s, 3H),  4.55 (d, 
3
J(H,H) = 6.1, 1H),  5.42 (d, 
3
J(H,H) = 12.5, 1H) 7.28-7.33 (m, 3H), 7.41-7.46 (m, 2H), 7.69 (d, 
3
J(H,H) = 12.6, 1H). 
13
C NMR (CDCl3, 100 MHz): = 25.69, 25.70, 26.2, 28.2, 28.6, 42.6, 51.0, 76.9, 84.5, 
88.6, 98.2, 122.0, 128.3 (2C), 128.8, 131.8 (2C), 161.0, 168.2. IR (CHCl3, cm
-1
) 3025.7, 
2933.3, 2856.9, 2227.4, 1704.3, 1641.6, 1623.4, 1490.8, 1438.5, 1322.2, 1294.3, 
1231.6, 1136.1. ES (70 eV): m/z (%): 298 (0.9) [M
+
], 197 (86), 155 (30), 141 (29), 129 
(29), 117 (46), 115 (100), 91(40).  HRMS calculated for C19H22O3 298.1569, found 
298.1575. 
Representative procedure for the microwave-assisted reaction of propargyl vinyl 
ethers 4 with primary amines: propargyl vinyl ether 4a (1.0 mmol) and p-anisidine 
(1.10 mmol) in toluene (1 mL) were placed in a microwave-special closed vial and the 
solution was irradiated for 1 hour in a single-mode microwave oven (150 Watt, 120 ºC). 
After removing the solvent at reduced pressure the products were purified by flash 
column chromatography (silica gel, n-hexane/EtOAc 85/15) to yield 8a (254 mg, 93%). 
Methyl 1-(4-methoxyphenyl)-6,6-dimethyl-1,6-dihydropyridine-3-carboxylate (8a): 
(254 mg, 93%) yellowish oil.  
1
H NMR (CDCl3, 400 MHz): = 1.23 (s, 6H), 3.64 (s, 
3H), 3.78 (s, 3H), 4.88 (d, 
3
J(H,H)= 9.9 Hz, 1H), 6.34 (d, 
3
J(H,H)= 9.9 Hz, 1H), 6.84 (d, 
3
J(H,H)= 8.8 Hz, 2H), 7.12 (d, 
3
J(H,H)= 8.8 Hz, 2H), 7.25 (s, 1H). 
13
C NMR (CDCl3, 100 
MHz): = 29.1 (2C), 50.6, 55.4, 58.4, 98.4, 114.0 (2C), 199.9, 120.6, 130.2 (2C), 
136.1, 146.7, 158.9, 167.0. IR (CHCl3, cm
-1
) 2964.1, 2842.0, 1683.0, 1640.6, 1557.4, 
1507.7, 1437.9, 1264.2, 1219.0, 1096.0. MS (70 eV): m/z (%): 273 (3.5) [M
+
], 259 (17), 
258 (100), 242 (3.6), 214 (3.5), 188 (2.7), 134 (4.7), 77 (7.1). HRMS calculated for 
C16H19NO3 273.1365, found 273.1369. 
Methyl 1-(4-methoxyphenyl)-6-methyl-6-phenyl-1,6-dihydropyridine-3-
carboxylate (8b): (308 mg, 92%) amorpous pale yellow solid. 
1
H NMR (CDCl3, 400 
MHz): = 1.65 (s, 3H), 3.70 (s, 3H), 3.73 (s, 3H), 4.99 (d, 3J(H,H)= 9.9 Hz, 1H), 6.44 
(dd, 
3
J(H,H)= 9.9 and 1.5 Hz, 1H), 6.64-6.70 (m, 4H), 7.24-7.28 (m, 1H), 7.29-7.31 (m, 
2H), 7.35 (s, 1H), 7.41-7.47 (m, 2H). 
13
C NMR (CDCl3, 100 MHz): = 26.8, 50.7, 55.4, 
63.9, 97.4, 113.7 (2C), 118.1, 121.4, 126.7 (2C), 127.6, 128.3 (2C), 128.9 (2C), 136.6, 
146.0, 146.8, 158.5, 167.1. IR (CHCl3, cm
-1
) 2975.6, 2947.2, 1678.9, 1645.5, 1547.4, 
1509.1, 1440.7, 1288.0, 1250.9, 1185.9, 1099.3. MS (70 eV): m/z (%): 335 (7.8) [M
+
], 
321 (25), 320 (100), 276 (16), 258 (59), 149 (11), 115 (11), 77 (25). HRMS calculated 
for C21H21NO3 335.1521, found 335.1519. 
Methyl 1-(4-methoxyphenyl)-6,6-diphenyl-1,6-dihydropyridine-3-carboxylate (8c): 
(373 mg, 94%) amorphous orange solid.
 1
H NMR (CDCl3, 400 MHz): = 3.62 (s, 3H), 
3.67 (s, 3H), 5.34 (d, 
3
J(H,H)= 9.6 Hz, 1H), 6.45-6.49 (m, 3H), 6.76 (d, 
3
J(H,H)= 9.1 Hz, 
2H), 7.15-7.18 (m, 2H), 7.21-7.24 (m, 4H), 7.31-7.33 (m, 4H), 7.61 (s, 1H). 
13
C NMR 
(CDCl3, 100 MHz): = 50.8, 55.3, 72.5, 100.3, 113.4 (2C), 118.0, 121.5, 127.2 (2C), 
127.8 (4C), 128.1 (2C), 128.7 (4C), 137.9, 143.6 (2C), 144.1, 157.7, 167.0. IR (CHCl3, 
cm
-1
) 3009.8, 2952.8, 1683.8, 1635.7, 1560.2, 1509.2, 1441.7, 1266.2, 1233.3, 1109.2. 
MS (70 eV): m/z (%): 397 (36) [M
+
], 339 (23), 338 (100), 320 (62), 203 (13), 202 (23), 
165 (23), 77 (24). HRMS calculated for C26H23NO3 397.1678, found 397.1667. 
Methyl 6-(4-methoxyphenyl)-6-azaspiro[4.5]deca-7,9-diene-8-carboxylate (8d): 
(281 mg, 94%) amorphous brown solid. 
1
H NMR (CDCl3, 400 MHz): = 1.36-1.45 (m, 
2H), 1.53-1.63 (m, 2H), 1.70-1.76 (m, 2H), 1.79-1.86 (m, 2H), 3.65 (s, 3H), 3.80 (s, 
3H), 5.06 (d, 
3
J(H,H)= 9.9 Hz, 1H), 6.36 (dd, 
3
J(H,H)= 9.9 and 1.5 Hz, 1H), 6.85 (d, 
3
J(H,H)= 9.1 Hz, 2H), 7.14 (d, 
3
J(H,H)= 9.1 Hz, 2H), 7.32 (d, 
3
J(H,H)= 1.5 Hz, 1H). 
13
C 
NMR (CDCl3, 100 MHz): = 22.3 (2C), 40.0 (2C), 50.6, 55.4, 68.5, 98.5, 114.1 (2C), 
119.0, 119.9, 130.5 (2C), 136.3, 147.6, 158.9, 167.0. IR (CHCl3, cm
-1
) 3010.4, 2953.0, 
1675.7, 1635.5, 1560.9, 1510.0, 1441.7, 1278.8, 1212.2. MS (70 eV): m/z (%): 299 (34) 
[M
+
], 271 (27), 270 (100), 207 (32), 175 (32), 160 (19), 121 (39). HRMS calculated for 
C18H21NO3 299.1521, found 299.1513. 
Methyl 1-(4-methoxyphenyl)-1-azaspiro[5.5]undeca-2,4-diene-3-carboxylate (8e): 
(291 mg, 93%) dark red oil. 
1
H NMR (CDCl3, 400 MHz): = 0.89-0.99 (m, 1H), 1.28-
1.35 (m, 2H), 1.49-1.58 (m, 5H), 1.98-2.01 (m, 2H), 3.66 (s, 3H), 3.80 (s, 3H), 5.35 (d, 
3
J(H,H)= 9.9 Hz, 1H), 6.48 (d, 
3
J(H,H)= 9.9 Hz, 1H), 6.85 (d, 
3
J(H,H)= 8.8 Hz, 2H), 7.11 (d, 
3
J(H,H)= 8.8 Hz, 2H), 7.32 (d, 
3
J(H,H)= 1.5 Hz, 1H). 
13
C NMR (CDCl3, 100 MHz): = 
21.3 (2C), 25.3, 36.0 (2C), 50.6, 55.5, 60.8, 99.1, 114.0 (2C), 115.7, 121.0, 130.9 (2C), 
135.7, 147.3, 159.0, 167.1. IR (CHCl3, cm
-1
) 2937.9, 2854.3, 1683.3, 1627.2, 1554.4, 
1508.0, 1440.7, 1222.2. MS (70 eV): m/z (%): 313 (31) [M
+
], 271 (28), 270 (100), 257 
(22), 256 (39), 242 (10), 134 (10), 123 (16), 121 (19). HRMS calculated for C19H23NO3 
313.1678, found 313.1683. 
Methyl 6-methyl-6-phenyl-1-((S)-1-phenylethyl)-1,6-dihydropyridine-3-
carboxylate (8g): (277 mg, 83%) orange oil. 2 Diastereomers separated by flash 
chromatography (60:40 of less polar:more polar). Major isomer: 
1
H NMR (CDCl3, 400 
MHz): = 1.31 (d, 3J(H,H)= 7.1 Hz, 3H), 1.56 (s, 3H), 3.72 (s, 3H), 4.23 (q, 
3
J(H,H)= 7.1 
Hz, 1H), 4.81 (d, 
3
J(H,H)= 10.1 Hz, 1H), 6.38 (dd, 
3
J(H,H)= 10.1 and 1.5 Hz, 1H), 7.24-
7.27 (m, 3H), 7.30-7.35 (m, 3H), 7.39-7.42 (m, 2H), 7.54-7.56 (m, 2H), 7.74 (s, 1H). 
13
C NMR (CDCl3, 100 MHz): = 23.4, 27.1, 50.6, 56.9, 64.7, 95.1, 117.7, 121.0, 125.8 
(2C), 127.0 (2C), 127.2, 127.7, 128.4 (2C), 128.8 (2C), 143.2, 144.1, 146.4, 167.1. 
Minor isomer: 
1
H NMR (CDCl3, 400 MHz): = 1.65 (d, 
3
J(H,H)= 7.1 Hz, 3H), 1.83 (s, 
3H), 3.68 (s, 3H), 4.28 (q, 
3
J(H,H)= 7.1 Hz, 1H), 4.81 (d, 
3
J(H,H)= 10.1 Hz, 1H), 6.41 (dd, 
3
J(H,H)= 10.1 and 1.5 Hz, 1H), 6.61 (dd, 
3
J(H,H)= 7.3 and 1.5 Hz, 2H), 7.06-7.10 (m, 3H), 
7.22-7.27 (m, 3H), 7.44-7.46 (m, 2H), 7.58 (s, 1H). 
13
C NMR (CDCl3, 100 MHz): = 
23.4, 25.5, 50.6, 56.1, 64.2, 95.5, 118.3, 120.1, 126.5 (2C), 127.2, 127.7, 128.0 (2C), 
128.2 (2C), 128.3 (2C), 141.4, 142.4, 145.3, 167.0. IR (major isomer) (CHCl3, cm
-1
) 
3009.9, 2950.4, 1671.6, 1638.3, 1563.0, 1434.7, 1321.2, 1254.3, 1128.2. MS (70 eV): 
m/z (%): 333 (65) [M
+
], 318 (77), 302 (15), 274 (32), 256 (23), 215 (17), 214 (100), 105 
(76). HRMS calculated for C22H23NO2 333.1729, found 333.1740. 
Methyl 6-(4-methoxyphenyl)-9-phenyl-6-azaspiro[4.5]deca-7,9-diene-8-carboxylate 
(8h): (311 mg, 83%) amorphous brown solid. 
1
H NMR (CDCl3, 400 MHz): = 1.47-
1.55 (m, 2H), 1.62-1.71 (m, 2H), 1.80-1.90 (m, 4H), 3.49 (s, 3H), 3.83 (s, 3H), 4.99 (s, 
1H), 6.90 (d, 
3
J(H,H)= 8.8 Hz, 2H), 7.20 (d, 
3
J(H,H)= 8.8 Hz, 2H), 7.24-7.32 (m, 5H), 7.61 
(s, 1H). 
13
C NMR (CDCl3, 100 MHz): = 22.0 (2C), 38.6 (2C), 50.3, 55.5, 68.8, 100.0, 
114.2 (2C), 120.9, 126.6, 127.4 (2C), 127.6 (2C), 130.2 (2C), 134.6, 136.0, 141.3, 
149.4, 158.9, 166.6. IR (CHCl3, cm
-1
) 3011.1, 2953.0, 1683.1, 1618.3, 1554.3, 1509.5, 
1438.5, 1283.6, 1240.4. MS (70 eV): m/z (%): 375 (59) [M
+
], 374 (19), 347 (40), 346 
(100), 332 (19), 123 (45), 121 (44). HRMS calculated for C24H25NO3 375.1834, found 
375.1836. 
Methyl 6-benzyl-9-phenyl-6-azaspiro[4.5]deca-7,9-diene-8-carboxylate (8i): (295 
mg, 82%) reddish oil. 
1
H NMR (CDCl3, 400 MHz): = 1.61-1.70 (m, 4H), 1.76-1.82 
(m, 2H), 1.85-1.92 (m, 2H), 3.46 (s, 3H), 4.49 (s, 2H), 4.90 (s, 1H), 7.21-7.30 (m, 8H), 
7.32-7.50 (m, 2H), 7.55 (s, 1H). 
13
C NMR (CDCl3, 100 MHz): = 23.1 (2C), 39.3 (2C), 
50.2, 53.7, 68.1, 98.9, 121.0, 126.3 (2C), 126.5, 127.3 (2C), 127.5, 127.6 (2C), 128.8 
(2C), 134.2, 138.6, 141.3, 149.9, 166.4. IR (CHCl3, cm
-1
) 3011.6, 2957.3, 2873.7, 
1678.5, 1623.7, 1562.4, 1495.7, 1438.2, 1395.7, 1354.8, 1324.1, 1298.8, 1225.2, 
1188.7, 1148.4, 1091.3. MS (70 eV): m/z (%): 359 (33) [M
+
], 331 (26), 330 (64), 317 
(35), 316 (18), 240 (20), 91 (100). HRMS calculated for C24H25NO2 359.1885, found 
359.1875. 
Methyl 4-methyl-1-phenyl-1-azaspiro[5.5]undeca-2,4-diene-3-carboxylate (8j): (226 
mg, 76%) amorphous pale solid.  Major tautomer (“4-methyl” group) 1H NMR (CDCl3, 
400 MHz): = 0.88-1.01 (m, 1H), 1.26-1.40 (m, 2H), 1.49-1.67 (m, 5H), 1.99 (d, 
3
J(H,H)= 11.1 Hz, 2H), 2.13 (s, 3H), 3.63 (s, 3H), 5.09 (s, 1H), 7.18-7.22 (m, 2H), 7.30-
7.38 (m, 3H), 7.45 (s, 1H). 
13
C NMR (CDCl3, 100 MHz): = 21.4, 21.5 (2C), 25.3, 35.7 
(2C), 50.3, 60.9, 100.7, 114.6, 127.6, 128.9 (2C), 129.8 (2C), 130.3, 142.9, 148.1, 
167.2. Minor tautomer (“4-methylene” group) 1H NMR (CDCl3, 400 MHz): = 0.88-
1.01 (m, 1H), 1.26-1.40 (m, 2H), 1.49-1.67 (m, 5H), 1.74 (d, 
3
J(H,H)= 11.1 Hz, 2H), 2.59 
(s, 2H), 3.66 (s, 3H), 4.79 (d, 
3
J(H,H)= 2.5 Hz, 1H), 5.73 (d, 
3
J(H,H)= 2.5 Hz, 1H), 7.12-
7.15 (m, 2H), 7.30-7.38 (m, 3H), 7.46 (s, 1H). 
13
C NMR (CDCl3, 100 MHz): = 21.7 
(2C), 25.3, 33.6 (2C), 40.1, 50.5, 60.0, 98.3, 108.8, 127.7, 128.9 (2C), 129.4 (2C), 
133.7, 143.1, 147.3, 167.4. IR (CHCl3, cm
-1
) 3011.9, 2943.2, 2860.0, 1733.1, 1678.3, 
1625.6, 1573.7, 1494.0, 1438.1, 1292.2, 1232.0, 1093.1. MS (70 eV): m/z (%): 297 (30) 
[M
+
], 255 (20), 254 (100), 241 (11), 240 (30), 93 (16), 77 (13). HRMS calculated for 
C19H23NO2 297.1729, found 297.1726. 
Methyl 1,4-dimethyl-1-azaspiro[5.5]undeca-2,4-diene-3-carboxylate (8k): (186 mg, 
79%) yellowish oil. Major tautomer (“4-methyl” group) 1H NMR (CDCl3, 400 MHz): 
= 1.03-1.25 (m, 1H), 1.44-1.70 (m, 7H), 1.78-1.88 (m, 2H), 2.04 (s, 3H), 2.96 (s, 3H), 
3.63 (s, 3H), 4.89 (s, 1H), 7.36 (s, 1H). 
13
C NMR (CDCl3, 100 MHz): = 21.3 (2C), 
21.4, 25.5, 33.4, 37.3 (2C), 50.1, 59.2, 98.4, 112.4, 130.5, 150.0, 167.2. Minor tautomer 
(“4-methylene” group) 1H NMR (CDCl3, 400 MHz): = 1.03-1.25 (m, 1H), 1.44-1.70 
(m, 7H), 1.78-1.88 (m, 2H), 2.42 (s, 2H), 2.95 (s, 3H), 3.67 (s, 3H), 4.65 (d, 
3
J(H,H)= 2.5 
Hz, 1H), 5.57 (d, 
3
J(H,H)= 2.5 Hz, 1H), 7.36 (s, 1H).
 13
C NMR (CDCl3, 100 MHz): = 
21.5 (2C), 25.5, 31.3, 37.2 (2C), 39.6, 50.3, 58.0, 107.2, 133.8, 149.1, 167.5. IR (CHCl3, 
cm
-1
) 3010.0, 2941.1, 2858.6, 1670.4, 1623.9, 1588.3, 1572.0, 1439.3, 1298.1, 1154.2, 
1068.7. MS (70 eV): m/z (%): 235 (21) [M
+
], 206 (8.7), 204 (7.3), 193 (18), 192 (100), 
179 (37). HRMS calculated for C14H21NO2 235.1572, found 235.1567. 
Methyl 1-(4-methoxyphenyl)-4-methyl-1-azaspiro[5.5]undeca-2,4-diene-3-
carboxylate (8l): (252 mg, 77%) amorphous pale brown solid. Major tautomer (“4-
methyl” group) 1H NMR (CDCl3, 400 MHz): = 0.90-0.98 (m, 1H), 1.23-1.36 (m, 2H), 
1.45-1.60 (m, 5H), 1.96 (d, 
3
J(H,H)= 11.1 Hz, 2H), 2.13 (s, 3H), 3.63 (s, 3H), 3.81 (s, 
3H), 5.06 (s, 1H), 6.86 (d, 
3
J(H,H)= 8.8 Hz, 2H), 7.12 (d, 
3
J(H,H)= 8.8 Hz, 2H), 7.42 (s, 
1H). 
13
C NMR (CDCl3, 100 MHz): = 21.4, 21.5 (2C), 25.3, 35.7 (2C), 50.2, 55.4, 
60.8, 100.2, 113.95 (2C), 114.0, 130.3, 130.8 (2C), 135.6, 145.6, 158.9, 167.2. Minor 
tautomer (“4-methylene” group) 1H NMR (CDCl3, 400 MHz): = 0.90-0.98 (m, 1H), 
1.23-1.36 (m, 2H), 1.45-1.60 (m, 5H), 1.71 (d, 
3
J(H,H)= 11.6 Hz, 2H), 2.58 (s, 2H), 3.66 
(s, 3H), 3.81 (s, 3H), 4.78 (d, 
3
J(H,H)= 2.5 Hz, 1H), 5.71 (d, 
3
J(H,H)= 2.5 Hz, 1H), 6.86 (d, 
3
J(H,H)= 8.8 Hz, 2H), 7.05 (d, 
3
J(H,H)= 8.8 Hz, 2H), 7.43 (s, 1H). 
13
C NMR (CDCl3, 100 
MHz): = 21.7 (2C), 25.3, 33.5 (2C), 40.1, 50.4, 55.4, 59.9, 97.8, 108.5, 114.4 (2C), 
130.5 (2C), 130.8, 135.8, 147.8, 158.9, 167.4. IR (CHCl3, cm
-1
) 3011.7, 2941.8, 2859.8, 
1677.8, 1625.2, 1573.9, 1509.5, 1438.4, 1292.3, 1249.2, 1170.2, 1093.3. MS (70 eV): 
m/z (%): 327 (32) [M
+
], 285 (21), 284 (100), 271 (13), 270 (24), 123 (15). HRMS 
calculated for C20H25NO3 327.1834, found 327.1828. 
 
Methyl 4-tert-butyl-1-(4-methoxyphenyl)-1-azaspiro[5.5]undeca-2,4-diene-3-
carboxylate (8m): (56 mg, 15%) amorphous pale brown solid. 
1
H NMR (CDCl3, 400 
MHz): = 1.20-1.27 (m, 2H), 1.29 (s, 9H), 1.45-1.58 (m, 6H), 1.96-1.99 (m, 2H), 3.63 
(s, 3H), 3.81 (s, 3H), 5.22 (s, 1H), 6.85 (d, 
3
J(H,H)= 9.1 Hz, 2H), 7.11 (d, 
3
J(H,H)= 9.1 Hz, 
2H), 7.44 (s, 1H). 
13
C NMR (CDCl3, 100 MHz): = 21.9 (2C), 25.5, 30.6 (3C), 34.7 
(2C), 34.9, 50.5, 55.5, 59.9, 101.9, 113.3, 113.9 (2C), 130.6 (2C), 135.8, 142.5, 149.1, 
158.8, 167.9. IR (CHCl3, cm
-1
) 2940.6, 1686.4, 1618.6, 1508.9, 1435.9, 1362.4, 1289.6, 
1247.9. MS (70 eV): m/z (%): 369 (16) [M
+
], 327 (24), 326 (100), 313 (16), 312 (24), 
296 (7.4), 282 (6.3). HRMS calculated for C23H31NO3 369.2304, found 369.2298. 
Methyl 6-butyl-1-(4-methoxyphenyl)-4,6-diphenyl-1,6-dihydropyridine-3-
carboxylate (8n): (367 mg, 81%) reddish oil. 
1
H NMR (CDCl3, 400 MHz): = 0.84 (t, 
3
J(H,H)= 7.3 Hz, 3H), 1.21-1.34 (m, 2H), 1.48-1.67 (m, 2H), 1.75-1.82 (m, 1H), 2.08-
2.16 (m, 1H), 3.50 (s, 3H), 3.74 (s, 3H), 4.80 (s, 1H), 6.68 (d, 
3
J(H,H)= 8.8 Hz, 2H), 6.74 
(d, 
3
J(H,H)= 8.8 Hz, 2H), 7.24-7.30 (m, 6H), 7.34 (t, 
3
J(H,H)= 7.3 Hz, 2H), 7.51 (d, 
3
J(H,H)= 
7.3 Hz, 2H), 7.65 (s, 1H). 
13
C NMR (CDCl3, 100 MHz): = 14.0, 22.9, 26.6, 36.9, 50.4, 
55.4, 67.8, 98.1, 113.7 (2C), 121.5, 126.5, 126.9 (2C), 127.3 (2C), 127.6 (2C), 127.7, 
128.2 (2C), 128.4 (2C), 133.9, 136.4, 141.4, 146.7, 148.4, 158.3, 166.6. IR (CHCl3, cm
-
1
) 2958.8, 1681.9, 1630.7, 1560.5, 1509.4, 1438.2, 1280.9, 1237.0, 1182.3, 1099.8. MS 
(70 eV): m/z (%): 453 (12) [M
+
], 397 (37), 396 (100), 394 (31), 320 (36), 123 (23). 
HRMS calculated for C30H31NO3 453.2304, found 453.2292. 
Methyl 1-(4-methoxyphenyl)-9-oxo-4-phenyl-1-azaspiro[5.5]undeca-2,4-diene-3-
carboxylate ethylene ketal (8o): (327 mg, 73%) amorphous brown solid. 
1
H NMR 
(CDCl3, 400 MHz): = 1.58-1.64 (m, 2H), 1.71-1.78 (m, 2H), 1.89-1.97 (m, 2H), 2.04-
2.07 (m, 2H), 3.50 (s, 3H), 3.82 (s, 3H), 3.84-3.93 (m, 4H), 5.22 (s, 1H), 6.89 (d, 
3
J(H,H)= 8.8 Hz, 2H), 7.18 (d, 
3
J(H,H)= 8.8 Hz, 2H), 7.26-7.33 (m, 5H), 7.61 (s, 1H). 
13
C 
NMR (CDCl3, 100 MHz): = 30.4 (2C), 31.9 (2C), 50.4, 55.5, 60.2, 64.2, 64.3, 100.8, 
107.7, 114.2 (2C), 115.4, 126.9, 127.5 (2C), 127.7 (2C), 130.3 (2C), 135.3, 136.9, 
141.2, 148.8, 159.0, 166.6. IR (CHCl3, cm
-1
) 3011.7, 2952.6, 1682.7, 1548.8, 1509.6, 
1438.5, 1368.7, 1281.2, 1236.2, 1172.3, 1105.7. MS (70 eV): m/z (%): 447 (8.9) [M
+
], 
404 (10), 388 (9.1), 347 (32), 346 (100), 332 (21), 123 (21). HRMS calculated for 
C27H29NO5 447.2046, found 447.2037. 
Methyl 9-benzyl-1-(4-methoxyphenyl)-4-phenyl-1,9-diazaspiro[5.5]undeca-2,4-
diene-3-carboxylate (8p): (360 mg, 75%) amorphous pale orange solid. 
1
H NMR 
(CDCl3, 400 MHz): = 1.73-1.78 (m, 2H), 1.98-2.04 (m, 2H), 2.32-2.37 (m, 2H), 2.70-
2.72 (m, 2H), 3.50 (s, 3H), 3.50 (s, 2H), 3.83 (s, 3H), 5.19 (s, 1H), 6.88-6.90 (m, 2H), 
7.16-7.18 (m, 2H), 7.25-7.32 (m, 10H), 7.64 (s, 1H). 
13
C NMR (CDCl3, 100 MHz): = 
34.7 (2C), 49.1 (2C), 50.4, 55.5, 59.5, 62.9, 100.8, 114.2 (2C), 116.2, 126.8, 127.0, 
127.5 (2C), 127.7 (2C), 128.2 (2C), 129.0 (2C), 130.6 (2C), 135.1, 136.3, 138.4, 141.3, 
148.9, 159.1, 166.6. IR (CHCl3, cm
-1
) 2927.7, 1683.9, 1616.7, 1549.8, 1509.0, 1438.4, 
1364.3, 1294.0, 1222.0, 1105.0. MS (70 eV): m/z (%): 480 (10) [M
+
], 451 (9.0), 389 
(15), 347 (34), 346 (65), 332 (34), 91 (100). HRMS calculated for C31H32N2O3 
480.2413, found 480.2418. 
Methyl 6-(but-3-en-1-yl)-1-(4-methoxyphenyl)-4-phenyl-1,6-dihydropyridine-3-
carboxylate (8q): (252 mg, 67%) dark brown oil. 
1
H NMR (400 MHz, CDCl3):  = 
1.62-1.71 (m, 1H), 2.00-2.08 (m, 1H),2.16-2.30 (m, 2H), 3.53 (s, 3H), 3.80 (s, 3H), 
4.59-4.64 (m, 1H), 4.99-5.08 (m, 2H), 5.19 (d, 
3
J(H,H) = 6.3 Hz, 1H), 5.78-5.90 (m, 1H), 
6.90-6.92 (m, 2H), 7.12-7.14 (m, 2H), 7.22-7.31 (m, 5H), 7.80 (d, 
3
J(H,H) = 1.5 Hz, 1H); 
13
C NMR (100 MHz, CDCl3):  =28.9, 32.6, 50.9, 56.0, 58.2, 104.4, 114.2, 115.2 (2C), 
115.8, 121.4 (2C), 127.2, 127.9 (2C), 128.0 (2C), 137.0, 138.1, 138.3, 141.4, 143.2, 
157.3, 167.0; IR (CHCl3, cm
-1
) 3009.0, 2950.2, 2840.0, 2360.3,  1684.5, 1618.3, 1557.7, 
1511.0, 1437.6, 1231.3, 1037.0. MS (70 eV): m/z (%): 375 (1.3) [M
+
], 321 (22), 320 
(100), 277 (9.2), 217 (4.2), 154 (2.7), 128 (4.1), 115 (4.9), 92 (4.1); HRMS: calculated 
for C24H25NO3: 375.1834, found: 375.1832. 
Methyl 6-cyclohexyl-1-(4-methoxyphenyl)-4-phenyl-1,6-dihydropyridine-3-
carboxylate (8r): (133 mg, 33%) dark brown oil. 
1
H NMR (400 MHz, CDCl3):  
=0.99-1.13 (m, 5H), 1.40-1.49 (m, 3H), 1.50-1.59 (m, 2H), 1.76-1.79 (m, 1H), 3.37 (s, 
3H), 3.67 (s, 3H), 4.40-4.43 (m, 1H), 4.95 (d, 
3
J(H,H) = 6.1 Hz, 1H), 6.74-6.78 (m, 2H), 
7.02-7.04 (m, 2H), 7.08-7.17 (m, 5H), 7.70 (d, 
3
J(H,H) = 1.3 Hz, 1H); 
13
C NMR (100 
MHz, CDCl3):  =26.0, 26.3, 26.4, 27.2, 28.5, 43.3, 50.5, 55.6, 63.8, 106.3, 113.1, 
114.8 (2C), 122.0 (2C), 126.7, 127.4 (2C), 127.5 (2C), 137.0, 138.7, 141.4, 144.3, 
156.9, 166.6; IR (CHCl3, cm
-1
) 3005.6, 2931.0, 2855.1, 2360.4, 1684.2, 1617.3, 1559.8, 
1511.1, 1438.1, 1231.7. MS (70 eV): m/z (%): 403 (1.0) [M
+
], 332 (3.8), 321 (28), 320 
(100), 277 (8.5), 217 (3.0), 123 (2.6), 115 (3.8), 92 (3.6); HRMS: calculated for 
C26H29NO3: 403.2147, found: 403.2133. 
Methyl 1-(4-methoxyphenyl)-4-phenyl-6-propyl-1,6-dihydropyridine-3-carboxylate 
(8s): (244 mg, 67%) dark brown oil. 
1
H NMR (400 MHz, CDCl3):  = 0.96 (t, 
3
J(H,H) = 
6.9 Hz, 3H), 1.52-1.55 (m, 4H), 3.53 (s, 3H), 3.81 (s, 3H), 4.57-4.61 (m, 1H), 5.20 (d, 
3
J(H,H) = 6.3 Hz, 1H), 6.90-6.92 (m, 2H), 7.13-7.15 (m, 2H), 7.27-7.31 (m, 5H), 7.80 (d, 
3
J(H,H) = 1.5 Hz, 1H); 
13
C NMR (100 MHz, CDCl3):  =14.1, 17.6, 35.5, 50.5, 55.6, 
58.3, 106.3, 114.4, 114.8 (2C), 121.0 (2C), 126.8, 127.5 (2C), 127.6 (2C), 136.3, 138.0, 
141.1, 142.8, 156.8, 166.6; IR (CHCl3, cm
-1
) 3009.0, 2960.3, 2839.8, 2360.5, 1684.4, 
1621.8, 1557.8, 1511.0, 1437.5, 1230.9, 1036.2. MS (70 eV): m/z (%): 363 (1.3) [M
+
], 
321 (25), 320 (100), 277 (8.1), 217 (3.1), 131 (4.0), 115 (3.0); HRMS: calculated for 







C NMR spectra of the new compounds are available in the 
Supporting Information. 
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